vimseltinib   Click here for help

GtoPdb Ligand ID: 11190

Synonyms: DCC-3014 | DCC3014 | example 10 [WO2014145025A2]
Compound class: Synthetic organic
Comment: The chemical structure submitted to the WHO for the INN vimseltinib is identical to that of the investigational, oral CSF1R inhibitor DCC-3014, via a PubChem structure match. The compound is claimed as example 10 in Deciphera Pharmaceuticals' patent WO2014145025A2, in which KIT proto-oncogene inhibitory activity is also noted [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 99.75
Molecular weight 431.21
XLogP 3.58
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(Nc1ncc(c(=O)n1C)c1ccc(c(n1)C)Oc1ccnc(c1)c1cnn(c1)C)C
Isomeric SMILES CC(Nc1ncc(c(=O)n1C)c1ccc(c(n1)C)Oc1ccnc(c1)c1cnn(c1)C)C
InChI InChI=1S/C23H25N7O2/c1-14(2)27-23-25-12-18(22(31)30(23)5)19-6-7-21(15(3)28-19)32-17-8-9-24-20(10-17)16-11-26-29(4)13-16/h6-14H,1-5H3,(H,25,27)
InChI Key TVGAHWWPABTBCX-UHFFFAOYSA-N
References
1. Ahn Y,Vogeti L, Caldwell TM, Kaufman MD, Flynn DL. (2014)
2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities.
Patent number: WO2014145025A2. Assignee: Deciphera Pharmaceuticals, Llc. Priority date: 15/03/2013. Publication date: 18/09/2014.